PROTARA THERAPEUTIC INC (TARA) Stock Price, Forecast & Analysis
NASDAQ:TARA • US74365U1079
TARA Key Statistics, Chart & Performance
The current stock price of TARA is 6.51 USD. In the past month the price increased by 29.17%. In the past year, price increased by 56.49%.
TARA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to TARA. When comparing the yearly performance of all stocks, TARA is one of the better performing stocks in the market, outperforming 89.47% of all stocks.
TARA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TARA. TARA has a great financial health rating, but its profitability evaluates not so good.
TARA Financial Highlights
Over the last trailing twelve months TARA reported a non-GAAP Earnings per Share(EPS) of -1.44. The EPS increased by 48.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -36.58% | ||
| ROE | -39.99% | ||
| Debt/Equity | 0 |
TARA Forecast & Estimates
13 analysts have analysed TARA and the average price target is 26.01 USD. This implies a price increase of 299.54% is expected in the next year compared to the current price of 6.51.
TARA Ownership
TARA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.94 | 409.148B | ||
| AMGN | AMGEN INC | 16.38 | 198.801B | ||
| GILD | GILEAD SCIENCES INC | 17.38 | 192.281B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.11 | 124.696B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.29 | 84.911B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.93 | 41.535B | ||
| INSM | INSMED INC | N/A | 31.724B | ||
| BIIB | BIOGEN INC | 12.92 | 28.841B | ||
| NTRA | NATERA INC | N/A | 28.695B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.07 | 20.396B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TARA
Company Profile
Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. The company is headquartered in New York City, New York and currently employs 28 full-time employees. The company went IPO on 2014-10-22. The Company’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The firm is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin (BCG), as well as a Phase II trial in pediatric patients with LMs. In addition, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.
Company Info
PROTARA THERAPEUTIC INC
345 Park Avenue South, 3rd Floor
New York City NEW YORK 10010 US
CEO: Jesse Shefferman
Employees: 28
Phone: 16468440337
PROTARA THERAPEUTIC INC / TARA FAQ
What does TARA do?
Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. The company is headquartered in New York City, New York and currently employs 28 full-time employees. The company went IPO on 2014-10-22. The Company’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The firm is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin (BCG), as well as a Phase II trial in pediatric patients with LMs. In addition, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.
What is the stock price of PROTARA THERAPEUTIC INC today?
The current stock price of TARA is 6.51 USD. The price decreased by -0.31% in the last trading session.
Does TARA stock pay dividends?
TARA does not pay a dividend.
How is the ChartMill rating for PROTARA THERAPEUTIC INC?
TARA has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is TARA stock listed?
TARA stock is listed on the Nasdaq exchange.
Can you provide the upcoming earnings date for PROTARA THERAPEUTIC INC?
PROTARA THERAPEUTIC INC (TARA) will report earnings on 2026-03-11, after the market close.